SCHEMBL14747883

SCHEMBL14747883

CCCOc1ccc(O)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.49
LTA4H P09960 1/20 0.47
ATM Q13315 2/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
CASP1 P29466 1/20 0.44
HTT P42858 1/20 0.44
CASP7 P55210 1/20 0.44
KMT2A Q03164 1/20 0.44
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HPGD P15428 1/20 0.41
CSNK2A1 P68400 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8864262 0.91 ESR1 (0.59) ESR1LTA4HMAPTMEN1ALDH1A1
SCHEMBL11071449 0.89 ESR1 (0.58) ESR1LTA4HTHRATHRB
SCHEMBL9699080 0.87 ESR1 (0.61) ESR1LTA4HMAPTMEN1TP53
SCHEMBL9697402 0.87 ESR1 (0.61) ESR1LTA4HMAPTMEN1TP53
SCHEMBL11796987 0.87 ESR1 (0.61) ESR1LTA4HMAPTMEN1TP53
SCHEMBL9699688 0.87 ESR1 (0.61) ESR1LTA4HMAPTMEN1TP53
SCHEMBL9651856 0.85 IDO1 (0.44) ESR1MAPTKDM4EMEN1TP53
SCHEMBL17549596 0.85 LTA4H (0.47) ESR1LTA4HATMMAPTKDM4E
SCHEMBL863092 0.84 MAPT (0.51) ESR1LTA4HATMMAPTKDM4E
SCHEMBL3717467 0.84 ESR1 (0.54) ESR1LTA4HKDM4EUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111378259-B Biodegradable PBAT/PLA composite material and preparation method and application thereof 叶平山 2022-08-23 CN disclosed
EP-2275413-B1 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders NOVARTIS AG (CH) 2013-03-06 EP disclosed